Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604. © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Citation

Roeland E Wasmann, Cornelis Smit, Eric P H van Dongen, René M J Wiezer, Jill Adler-Moore, Yvo M de Beer, David M Burger, Catherijne A J Knibbe, Roger J M Brüggemann. Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 May 06;70(10):2213-2215

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 31588493

View Full Text